Amedeo Smart

Free Medical Literature Service

 

Amedeo

Hepatitis C
  Free Subscription

Articles published in
J Hepatol
    April 2026
  1. KINAST V, Desert R, Bartenschlager R, Baumert TF, et al
    Renewed momentum for HCV and HCC research.
    J Hepatol. 2026 Apr 22:S0168-8278(26)00188-1. doi: 10.1016/j.jhep.2026.
    >> Share

    March 2026
  2. BATISTA MN, Bordignon J, Pamplona Mosimann AL, Bobrowski T, et al
    An immunocompetent murine model of virus-elicited liver fibrosis and hepatocellular carcinoma.
    J Hepatol. 2026 Mar 11:S0168-8278(26)00085-1. doi: 10.1016/j.jhep.2026.
    >> Share

    November 2025
  3. LLIBRE JM, Boesecke C, Moon J, Lank PM, et al
    A phase IIIb study of 8-week glecaprevir/pibrentasvir treatment in adults with acute hepatitis C.
    J Hepatol. 2025 Nov 24:S0168-8278(25)02625-X. doi: 10.1016/j.jhep.2025.
    >> Share

    July 2025
  4. SANDMANN L
    From HCV to HEV: Repurposing a nucleoside analogue for hepatitis E therapy.
    J Hepatol. 2025 Jul 31:S0168-8278(25)02322-0. doi: 10.1016/j.jhep.2025.
    >> Share

    April 2025
  5. HOUGHTON M
    A rat hepacivirus model to aid hepatitis C viral vaccine development ?
    J Hepatol. 2025 Apr 16:S0168-8278(25)00243-0. doi: 10.1016/j.jhep.2025.
    >> Share

  6. FERNANDES FF, Ferreira da Silva PG, Villela Nogueira CA
    Follow-up NIT values rather than their variation predict hepatocellular carcinoma after HCV eradication.
    J Hepatol. 2025 Apr 12:S0168-8278(25)00237-5. doi: 10.1016/j.jhep.2025.
    >> Share

  7. LUHMANN N, Wedemeyer H
    More than 10 years of IFN-free HCV treatment and viral hepatitis elimination: Mission not completed!
    J Hepatol. 2025 Apr 8:S0168-8278(25)00220-X. doi: 10.1016/j.jhep.2025.
    >> Share

  8. JIN F, Gridley J, Kumari A, Saeidi A, et al
    Hyperfunctional T cell responses unchecked by regulatory T cells are unable to resolve hepaciviral infection without humoral contribution.
    J Hepatol. 2025;82:604-614.
    >> Share

    March 2025
  9. THORSELIUS CE, Wolfisberg R, Fahnoe U, Scheel TKH, et al
    Norway rat hepacivirus resembles hepatitis C virus in terms of intra-host evolution and escape from neutralizing antibodies.
    J Hepatol. 2025 Mar 15:S0168-8278(25)00163-1. doi: 10.1016/j.jhep.2025.
    >> Share

  10. SANCHEZ-TORRIJOS Y, Fernandez-Alvarez P, Rosales JM, Perez-Estrada C, et al
    Recompensation of decompensated cirrhosis in hepatitis C patients after SVR: Prognostic implications.
    J Hepatol. 2025 Mar 6:S0168-8278(25)00153-9. doi: 10.1016/j.jhep.2025.
    >> Share

    February 2025
  11. NAHON P, Lusivika-Nzinga C, Merle P, Zoulim F, et al
    Value of non-invasive test dynamics in guiding HCC surveillance decisions after HCV cure in patients with cirrhosis.
    J Hepatol. 2025 Feb 26:S0168-8278(25)00084-4. doi: 10.1016/j.jhep.2025.
    >> Share

  12. RAZAVI HA, Waked I, Qureshi H, Kondili LA, et al
    Number of people treated for hepatitis C virus infection in 2014-2023 and applicable lessons for new HBV and HDV therapies.
    J Hepatol. 2025 Feb 4:S0168-8278(25)00020-0. doi: 10.1016/j.jhep.2025.
    >> Share

    December 2024
  13. WANG C, Tian H, Shang J
    Assessment of methods in E1E2 versus E2 immunogen studies for HCV vaccine research.
    J Hepatol. 2024 Dec 17:S0168-8278(24)02778-8. doi: 10.1016/j.jhep.2024.
    >> Share

    October 2024
  14. LIU CH, Cheng PN, Fang YJ, Chen CY, et al
    Risk of de novo HCC in patients with MASLD following direct-acting antiviral-induced cure of HCV infection.
    J Hepatol. 2024 Oct 3:S0168-8278(24)02578-9. doi: 10.1016/j.jhep.2024.
    >> Share

  15. PAPATHEODORIDI M, De Ledinghen V, Lupsor-Platon M, Bronte F, et al
    Agile scores in MASLD and ALD: External validation and their utility in clinical algorithms.
    J Hepatol. 2024;81:590-599.
    >> Share

    September 2024
  16. LIN H, Cheuk-Fung Yip T, Lee HW, Meng X, et al
    AI-Safe-C Score: Assessing Liver-Related Event Risks in Non-Cirrhotic Patients after Successful Direct-Acting Antiviral Treatment.
    J Hepatol. 2024 Sep 20:S0168-8278(24)02560-1. doi: 10.1016/j.jhep.2024.
    >> Share

    August 2024
  17. KIM SY, Shin EC
    Reply to: "Regulatory T cells dynamics during and after chronic hepatitis C treatment".
    J Hepatol. 2024 Aug 19:S0168-8278(24)02476-0. doi: 10.1016/j.jhep.2024.
    >> Share

    July 2024
  18. SOLIMAN R, Hassan A, Shiha G
    Regulatory T Cells dynamics during and after Chronic Hepatitis C treatment.
    J Hepatol. 2024 Jul 20:S0168-8278(24)02417-6. doi: 10.1016/j.jhep.2024.
    >> Share

  19. MINAMI T, Fujishiro M, Tateishi R
    Reply to: "Validation of SMART Model for HCC Risk stratification in genotype -4 HCV Patients following SVR and its comparison with GES score".
    J Hepatol. 2024 Jul 9:S0168-8278(24)02361-4. doi: 10.1016/j.jhep.2024.
    >> Share

  20. KUNDU J, Le HT, Logan M, Hockman D, et al
    Recombinant H77C gpE1/gpE2 heterodimer elicits superior HCV cross-neutralisation than H77C gpE2 alone.
    J Hepatol. 2024 Jul 8:S0168-8278(24)02335-3. doi: 10.1016/j.jhep.2024.
    >> Share

    June 2024
  21. KIM SY, Koh JY, Lee DH, Kim HD, et al
    Epigenetic scars in regulatory T cells are retained after successful treatment of chronic hepatitis C with direct-acting antivirals.
    J Hepatol. 2024 Jun 13:S0168-8278(24)02317-1. doi: 10.1016/j.jhep.2024.
    >> Share

    May 2024
  22. REIBERGER T, Lens S, Cabibbo G, Nahon P, et al
    EASL position paper on clinical follow-up after HCV cure.
    J Hepatol. 2024 May 30:S0168-8278(24)00275-7. doi: 10.1016/j.jhep.2024.
    >> Share

  23. SHIHA G, Mikhail N, Soliman R
    Validation of SMART Model for HCC Risk stratification in genotype -4 HCV Patients following SVR and its comparison with GES score.
    J Hepatol. 2024 May 15:S0168-8278(24)00348-9. doi: 10.1016/j.jhep.2024.
    >> Share

    April 2024
  24. KENNEDY MJ, Fernbach S, Scheel TKH
    Animal hepacivirus models for hepatitis C virus immune responses and pathology.
    J Hepatol. 2024 Apr 24:S0168-8278(23)05373-4. doi: 10.1016/j.jhep.2023.
    >> Share

  25. UNDERWOOD AP, Gupta M, Wu BR, Eltahla AA, et al
    B cell characteristics define HCV reinfection outcome.
    J Hepatol. 2024 Apr 9:S0168-8278(24)00271-X. doi: 10.1016/j.jhep.2024.
    >> Share

    March 2024
  26. SEMMLER G, Alonso Lopez S, Pons M, Lens S, et al
    Post-treatment LSM rather than change during treatment predicts decompensation in patients with cACLD after HCV cure.
    J Hepatol. 2024 Mar 21:S0168-8278(24)00198-3. doi: 10.1016/j.jhep.2024.
    >> Share

  27. SHEEHAN Y, Grebely J, Lloyd AR
    Reply to: " 'One-stop-shop' point-of-care hepatitis C RNA testing intervention in the prison - some issues".
    J Hepatol. 2024;80:e107-e108.
    >> Share

    February 2024
  28. BIALLAS R, Zimmermann R, Dudareva S
    Reply to: Population-based screening works: Effect of integrating screening for hepatitis B and C into the general health check-up in Germany.
    J Hepatol. 2024 Feb 23:S0168-8278(24)00133-8. doi: 10.1016/j.jhep.2024.
    >> Share

  29. LIU C, Guo C, Liu K
    Changes of hepatic myeloid cells in chronic viral hepatitis and after cure and their clinical significance.
    J Hepatol. 2024 Feb 6:S0168-8278(24)00121-1. doi: 10.1016/j.jhep.2024.
    >> Share

    January 2024
  30. HEO M, Norton BL, Pericot-Valverde I, Mehta SH, et al
    Optimal Hepatitis C Treatment Adherence Patterns and Sustained Virologic Response. among People Who Inject Drugs: The HERO Study.
    J Hepatol. 2024 Jan 17:S0168-8278(23)05374-6. doi: 10.1016/j.jhep.2023.
    >> Share

  31. HACHICHA-MAALEJ N, Collins IJ, Ades AE, Scott K, et al
    Corrigendum to "Modelling the potential effectiveness of hepatitis C screening and treatment strategies during pregnancy in Egypt and Ukraine" [J Hepatol (2023) 937-946].
    J Hepatol. 2024 Jan 4:S0168-8278(23)05367-9. doi: 10.1016/j.jhep.2023.
    >> Share

  32. THOMPSON LA, Charlton CL
    Evaluation and comparison of risk-based and universal HCV screening programs.
    J Hepatol. 2024 Jan 3:S0168-8278(24)00005-9. doi: 10.1016/j.jhep.2023.
    >> Share

    November 2023
  33. COLASANTI O, Burm R, Huang HE, Riedl T, et al
    Corrigendum to "Comparison of HAV and HCV infections in vivo and in vitro reveals distinct patterns of innate immune evasion and activation" [J Hepatol (2023) 645-656].
    J Hepatol. 2023 Nov 30:S0168-8278(23)05282-0. doi: 10.1016/j.jhep.2023.
    >> Share

    August 2023
  34. DAI CY, Batsaikhan B, Huang CF
    'One-stop-shop' point-of-care hepatitis C RNA testing intervention in the prison: some issues.
    J Hepatol. 2023 Aug 8:S0168-8278(23)05050-X. doi: 10.1016/j.jhep.2023.
    >> Share

    July 2023
  35. MARTIN MT, Patel S, Chacra W
    Pellet-based hepatitis C virus treatment with glecaprevir/pibrentasvir: a case report of an adult with short bowel syndrome.
    J Hepatol. 2023 Jul 27:S0168-8278(23)04997-8. doi: 10.1016/j.jhep.2023.
    >> Share

    June 2023
  36. MINAMI T, Sato M, Toyoda H, Yasuda S, et al
    Machine learning for individualized prediction of hepatocellular carcinoma development after the eradication of hepatitis C virus with antivirals.
    J Hepatol. 2023 Jun 24:S0168-8278(23)00424-5. doi: 10.1016/j.jhep.2023.
    >> Share

  37. THOMPSON LA, Plitt SS, Doucette K, Coffin CS, et al
    Evaluation and comparison of risk-based and universal prenatal HCV screening programs in Alberta, Canada.
    J Hepatol. 2023 Jun 20:S0168-8278(23)00419-1. doi: 10.1016/j.jhep.2023.
    >> Share

  38. PATEL S, Moser A, Domingo H
    Sustained virologic response in DAA-treated HCV patients on anti-epileptic drugs.
    J Hepatol. 2023 Jun 2:S0168-8278(23)00347-1. doi: 10.1016/j.jhep.2023.
    >> Share

    May 2023
  39. DENG H, Pan Y
    The influence of invasive procedures on acute HBV and HCV infections.
    J Hepatol. 2023 May 10:S0168-8278(23)00326-4. doi: 10.1016/j.jhep.2023.
    >> Share

    April 2023
  40. KONDILI LA, Rumi MG, Craxi A
    Hospital HCV elimination in addition to universal precautions could reduce incidence and infection burden in Italy.
    J Hepatol. 2023 Apr 28:S0168-8278(23)00310-0. doi: 10.1016/j.jhep.2023.
    >> Share

  41. COLASANTI O, Burm R, Huang HE, Riedl T, et al
    Comparison of HAV and HCV infections in vivo and in vitro reveals distinct patterns of innate immune evasion and activation.
    J Hepatol. 2023 Apr 28:S0168-8278(23)00309-4. doi: 10.1016/j.jhep.2023.
    >> Share

  42. SHEEHAN Y, Cunningham EB, Cochrane A, Byrne M, et al
    A 'one-stop-shop' point-of-care hepatitis C RNA testing intervention to enhance treatment uptake in a reception prison: the PIVOT study.
    J Hepatol. 2023 Apr 26:S0168-8278(23)00242-8. doi: 10.1016/j.jhep.2023.
    >> Share

  43. EL-KASSAS M, Emadeldeen M, Hassany M, Esmat G, et al
    A randomized controlled trial of SOF/VEL/VOX with or without ribavirin for retreatment of chronic hepatitis C.
    J Hepatol. 2023 Apr 21:S0168-8278(23)00234-9. doi: 10.1016/j.jhep.2023.
    >> Share

  44. CROUCHET E, Baumert TF
    Unraveling the role of the liver myeloid compartment during hepatitis C virus cure.
    J Hepatol. 2023 Apr 21:S0168-8278(23)00239-8. doi: 10.1016/j.jhep.2023.
    >> Share

    March 2023
  45. TOSETTI G, Degasperi E, Farina E, Primignani M, et al
    Carvedilol to reduce the risk of decompensation in patients with compensated cirrhosis: really needed also in patients with HCV cured or HBV suppressed viral cirrhosis?
    J Hepatol. 2023 Mar 30:S0168-8278(23)00203-9. doi: 10.1016/j.jhep.2023.
    >> Share

  46. CUI A, Li B, Wallace MS, Gonye ALK, et al
    Single-cell atlas of the liver myeloid compartment before and after cure of chronic viral hepatitis.
    J Hepatol. 2023 Mar 25:S0168-8278(23)00190-3. doi: 10.1016/j.jhep.2023.
    >> Share

  47. CAMINADA S, Mele A, Ferrigno L, Alfonsi V, et al
    Risk of parenterally transmitted hepatitis following exposure to invasive procedures in Italy: SEIEVA surveillance 2000-2021.
    J Hepatol. 2023 Mar 17:S0168-8278(23)00177-0. doi: 10.1016/j.jhep.2023.
    >> Share

  48. CARSON JM, Barbieri S, Matthews GV, Dore GJ, et al
    Corrigendum to 'National trends in retreatment of HCV due to reinfection or treatment failure in Australia' (J Hepatol [2023] 260-270).
    J Hepatol. 2023 Mar 8:S0168-8278(23)00109-5. doi: 10.1016/j.jhep.2023.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016